1
|
Rushendran R, Begum RF, Singh S A, Narayanan PL, Vellapandian C, Prajapati BG, Paul PK. Navigating neurological disorders: harnessing the power of natural compounds for innovative therapeutic breakthroughs. EXCLI JOURNAL 2024; 23:534-569. [PMID: 38741726 PMCID: PMC11089094 DOI: 10.17179/excli2024-7051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2024] [Accepted: 03/07/2024] [Indexed: 05/16/2024]
Abstract
Novel treatments are needed as neurological issues become more frequent worldwide. According to the report, plants, oceans, microorganisms, and animals contain interesting drug discovery compounds. Alzheimer's, Parkinson's, and stroke reviews emphasize neurological disorders' complexity and natural substances' safety. Learn about marine-derived and herbal substances' neuroprotective characteristics and applications. Molecular pathways show these substances' neurological healing effects. This article discusses clinical usage of Bryostatin-1, Fucoidan, Icariin, Salvianolic acid, Curcumin, Resveratrol, etc. Their potential benefits for asthma and Alzheimer's disease are complex. Although limited, the study promotes rigorous scientific research and collaboration between traditional and alternative medical practitioners. Unexplored natural compounds, quality control, well-structured clinical trials, and interdisciplinary collaboration should guide future study. Developing and employing natural chemicals to treat neurological illnesses requires ethical sourcing, sustainability, and public awareness. This detailed analysis covers natural chemicals' current state, challenges, and opportunities in neurological disorder treatment. See also the graphical abstract(Fig. 1).
Collapse
Affiliation(s)
- Rapuru Rushendran
- Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Tamil Nadu, India
| | - Rukaiah Fatma Begum
- Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Tamil Nadu, India
| | - Ankul Singh S
- Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Tamil Nadu, India
| | - Pavithra Lakshmi Narayanan
- Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Tamil Nadu, India
| | - Chitra Vellapandian
- Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Tamil Nadu, India
| | - Bhupendra G. Prajapati
- Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 384012, Gujarat, India
| | - Pijush Kumar Paul
- Department of Pharmacy, Gono Bishwabidyalay University, Mirzanagar, Savar, Dhaka-1344, Bangladesh
| |
Collapse
|
2
|
Antunes FTT, de Souza AH, Caminski ES, Greggio S, Venturin GT, da Costa JC, Taffarel M, Rebelo IN, Gomez MV, Correa DS, Vilanova FN, Regner AP, Dallegrave E. Neuroprotective effects of the CTK 01512-2 toxin against neurotoxicity induced by 3-nitropropionic acid in rats. Neurotoxicology 2021; 87:30-42. [PMID: 34478769 DOI: 10.1016/j.neuro.2021.08.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/28/2021] [Accepted: 08/28/2021] [Indexed: 01/07/2023]
Abstract
The mitochondrial inhibitor 3-nitropropionic acid (3-NP) induces excitotoxicity. The authors hypothesized that CTK 01512-2, a recombinant peptide calcium channel N-type blocker, and the TRPA1 antagonist, could show neuroprotective effects. The male Wistar rats received 3-NP [25 mg/kg (i.p.) for 7 days], and a treatment of CTK 01512-2 was delivered intrathecally (i.t.), thrice a week. The neuroprotective effects were evaluated by [18F]FDG MicroPET analysis. The CTK 01512-2 toxin was able to reestablish similar glucose uptakes on the control animals. To detect the neurobehavioral effects from 3-NP, three protocols (6.25, 12.5, 18.75 mg/kg of 3-NP (i.p.), for 3, 4, and 6 days, respectively) were evaluated by performance tests (open field test, walk footprint, elevated plus-maze, Y-maze, and the object recognition test). Important disabilities in the gait of the rats were seen, as well as memory deficits, and anxious behavior in the animals that were treated with all 3-NP protocols. The dose of 18.75 mg/kg (for 3 days) showed the most pronounced behavioral effects and lethality, while the rats treated with 12.5 mg/kg (for 4 days) showed behavioral effects similar to the 6.25 mg/kg dose (for 6 days). The third protocol was then repeated and the rats were treated with the CTK 01512-2 toxin to be evaluated behaviorally again. The recombinant peptide prevented all of the gait-evaluated parameters that were induced by 3-NP at a 6.25 mg/kg dose, which displayed an improvement in the exploratory activities. Overall, these results have reinforced the positive effects of CTK 01512-2 against the behavioral changes that were induced by the mitochondrial inhibitor 3-NP.
Collapse
Affiliation(s)
- Flavia Tasmin Techera Antunes
- Program of Postgraduation in Cellular and Molecular Biology Applied to Health, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.
| | - Alessandra Hubner de Souza
- Program of Postgraduation in Cellular and Molecular Biology Applied to Health, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.
| | - Emanuelle Sistherenn Caminski
- Laboratory of Toxicology Research, The Federal University of Health Science of Porto Alegre (UFCSPA), Rio Grande do Sul, Brazil.
| | - Samuel Greggio
- Centro de Pesquisa Pré-Clínica, Instituto do Cérebro do Rio Grande do Sul, Brain Institute (Brains), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, 90610-000, Brazil.
| | - Gianina Teribele Venturin
- Centro de Pesquisa Pré-Clínica, Instituto do Cérebro do Rio Grande do Sul, Brain Institute (Brains), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, 90610-000, Brazil.
| | - Jaderson Costa da Costa
- Centro de Pesquisa Pré-Clínica, Instituto do Cérebro do Rio Grande do Sul, Brain Institute (Brains), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, 90610-000, Brazil.
| | - Maitê Taffarel
- Laboratory of Pharmacy, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.
| | - Isadora Nunes Rebelo
- Laboratory of Pharmacy, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.
| | - Marcus Vinicius Gomez
- Institute of Teaching and Research of Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
| | - Dione Silva Correa
- Department of Chemistry, Lutheran University of Brazil, Canoas, RS, Brazil.
| | | | - Andrea Pereira Regner
- Program of Postgraduation in Cellular and Molecular Biology Applied to Health, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.
| | - Eliane Dallegrave
- Laboratory of Toxicology Research, The Federal University of Health Science of Porto Alegre (UFCSPA), Rio Grande do Sul, Brazil.
| |
Collapse
|
3
|
Turner A, Kaas Q, Craik DJ. Hormone-like conopeptides - new tools for pharmaceutical design. RSC Med Chem 2020; 11:1235-1251. [PMID: 34095838 PMCID: PMC8126879 DOI: 10.1039/d0md00173b] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 09/11/2020] [Indexed: 12/24/2022] Open
Abstract
Conopeptides are a diverse family of peptides found in the venoms of marine cone snails and are used in prey capture and host defence. Because of their potent activity on a range of mammalian targets they have attracted interest as leads in drug design. Until recently most focus had been on studying conopeptides having activity at ion channels and related neurological targets but, with recent discoveries that some conopeptides might play hormonal roles, a new area of conopeptide research has opened. In this article we first summarize the canonical pharmaceutical families of Conus venom peptides and then focus on new research relating to hormone-like conopeptides and their potential applications. Finally, we briefly examine methods of chemically stabilizing conopeptides to improve their pharmacological properties. A summary is presented of conopeptides in clinical trials and a call for future work on hormone-like conopeptides.
Collapse
Affiliation(s)
- Ashlin Turner
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland 4072 Australia
| | - Quentin Kaas
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland 4072 Australia
| | - David J Craik
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland 4072 Australia
| |
Collapse
|